This site is intended for healthcare professionals

European Commission approves Opdivo as adjuvant treatment for esophageal or gastroesophageal junction cancer patients with residual pathologic disease following chemoradiotherapy.- BMS

Read time: 1 mins
Last updated:1st Aug 2021
Published:1st Aug 2021
Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction (GEJ) cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT).
Condition: Gastric /Junction/Esophageal Adenocarcinoma
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest